Mission

As a global company dedicated to human health for more than 120 years, Johnson & Johnson has a deep and abiding commitment to use its expertise and resources to help enhance health care for people suffering from HIV/AIDS. Johnson & Johnson aspires to make a difference in the lives of those infected and affected by HIV/AIDS through:

• Developing effective new medicines and diagnostics for HIV and related opportunistic infections;
• Enhancing access to the company’s products as well as patient care and support;
• Providing contributions to assist communities and individuals at risk for HIV; and
• Meeting obligations to company employees through HIV/AIDS workplace programs.

Global Workplace Policy

Johnson & Johnson also has created a global workplace policy on HIV/AIDS that guarantees four fundamental rights:

• Non-discrimination and confidentiality protections;
• Voluntary counseling and testing programs;
• Care, support and treatment for HIV positive employees and their dependents with HIV; and
• Prevention, education and awareness programs for all employees of Johnson & Johnson and employees’ dependents.

Johnson & Johnson HIV/AIDS Programs

Johnson & Johnson supports over 30 programs worldwide that aid in the fight against HIV/AIDS.

Total Control of the Epidemic (The International Humana People to People Movement)

Created by Humana People to People, The Total Control of the Epidemic (TCE) Program has reached more than 2.5 million people through door-to-door outreach since its inception in 2000. The program trains field representatives to educate others in the high-risk areas of Botswana, South Africa, Mozambique, and Zimbabwe. For three years running, Johnson & Johnson has supported a TCE program in Bramfishersville, Soweto, where few health facilities exist and most people have little or no access to treatment or care. Since the Soweto program’s launch in 2003, the project has registered 19,000 homes, providing 78,000 home education sessions and 1,700 mother-to-child prevention instructions to pregnant women.

The Elizabeth Glaser Pediatric AIDS Foundation

The Elizabeth Glaser Pediatric AIDS Foundation partners with Johnson & Johnson to reduce mother-to-child transmission of HIV in developing countries. The project, known as The Call to Action Project, was established in 2000 and brings simplified regimes for prevention of mother-to-child transmission of HIV to over 17 countries. As of January 1, 2007, the Foundation is working in more than 1,500 sites, reaching more than 3.2 million women with access to services to prevent transmission of HIV from mothers to babies. More than 2.5 million women have been tested for HIV through these initiatives. The Foundation is currently supporting PMTCT programs in Cameroon, China, Côte d’Ivoire, the Democratic Republic of Congo, Dominican Republic, India, Kenya, Lesotho, Malawi, Mozambique, Russia, Rwanda, South Africa, Swaziland, Tanzania, Uganda, Zambia and Zimbabwe.

Mothers2Mothers

Mothers2Mothers, a South African organization, helps provide for children with HIV-positive mothers. The initiative offers HIV-positive pregnant women and new mothers medical, social and emotional support, which empowers these women to protect their own health and the health of their babies. The program was established as a counseling service and connects HIV-positive new mothers, known as “mentor mothers,” with HIV-positive pregnant women accessing services to prevent mother-to-child transmission of HIV. The program has expanded to provide treatment and support to mothers and babies during the critical first year after delivery. Mentor mothers teach the expectant HIV-positive mothers infant feeding techniques and life skills necessary to adjust to their communities as women and mothers living with HIV/AIDS. In 2005, with the support of Johnson & Johnson, the first Mothers2Mothers site was opened at the Frere Hospital in the Eastern Cape, East London, which now serves more than 10,000 women. The program currently operates 65 sites in five provinces in South Africa.

UCLA Management Development Institute

Through a partnership with the African Medical Research Foundation, Johnson & Johnson and the UCLA HIV/AIDS Management Development Institute has launched a one-week intensive program designed to enhance the management skills of program leaders and supervisors of East African community-based groups, hospitals, and educational institutions. The program focuses on developing individual administrative proficiency within HIV/AIDS prevention, treatment, care, and support services settings. Offered in cooperation with faculty from several local universities, the curriculum’s aim is to increase the quantity and quality of health care in the region. The inaugural program was held in Kenya in 2006 with 35 providers from seven African nations.

International Partnership for Microbicides, Tibotec
Pharmaceuticals

In 2004, Tibotec Pharmaceuticals Ltd., a Johnson & Johnson subsidiary, established a first-of-its-kind partnership with the International Partnership on Microbicides (IPM) to provide a royalty-free license and technology transfer to develop, manufacture and distribute Dapivirine gel (TMC120) as a topical vaginal microbicide to help protect women from HIV infection in developing countries. Currently undergoing trials in Rwanda, Tanzania, South Africa and Uganda, Dapivirene gel is the first microbicide containing antiretrovirals to be tested in Africa. As a result of this partnership, two other major pharmaceutical companies agreed to grant IPM similar royalty-free licenses for additional compounds. In addition to developing microbicides, Tibotec discovers and develops new antiretrovirals including protease inhibitors, non-nucleoside reverse transcriptase inhibitors and other products.

Mission for Essential Drugs & Supplies

Since 2000, Tibotec, a Johnson & Johnson company, has either donated or sold at cost over two million patient treatments of micMAT(miconazole nitrate 10 muco-adhesive buccal tablet), also known as Tibozole™, an anti-fungal medication used in the treatment of oral candidasis or thrush, an infection common in late-stage AIDS patients. micMAT has a dramatic impact on quality of life by rapidly restoring an HIV/AIDS patient's ability to eat. Tibotec partnered with the Mission for Essential Drugs & Supplies on the MAT Award Program in 2003, and has since utilized profits from the cost recovery distribution program to award grants to NGOs and public health facilities throughout Kenya that support sustained community initiatives.

HIV South Africa

The Johnson & Johnson Home-Based Care Program, developed and implemented in partnership with HIV South Africa (HIVSA), helps the greater Soweto region cope with the increasing number of HIV patients being cared for at home. The Johnson & Johnson (Pty.) Limited consumer manufacturing plant in East London provides HIVSA with regular donations of personal care products and over-the-counter medications. HIVSA then delivers these basic health supplies to a network of 35 community-based organizations that provide in-home care. HIVSA also trains and monitors organizations and their staff on appropriate use of the products.